GSA Capital Partners LLP Makes New Investment in Autolus Therapeutics plc (NASDAQ:AUTL)

GSA Capital Partners LLP bought a new position in Autolus Therapeutics plc (NASDAQ:AUTL) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 298,086 shares of the company’s stock, valued at approximately $1,082,000.

Several other hedge funds also recently modified their holdings of the business. Privium Fund Management B.V. increased its stake in shares of Autolus Therapeutics by 15.6% during the 3rd quarter. Privium Fund Management B.V. now owns 185,639 shares of the company’s stock worth $674,000 after purchasing an additional 25,000 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Autolus Therapeutics by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock worth $139,000 after purchasing an additional 14,959 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in shares of Autolus Therapeutics by 9.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company’s stock worth $152,000 after purchasing an additional 3,740 shares during the last quarter. Herbst Group LLC acquired a new position in shares of Autolus Therapeutics during the 3rd quarter worth $91,000. Finally, Millennium Management LLC increased its stake in shares of Autolus Therapeutics by 113.7% during the 2nd quarter. Millennium Management LLC now owns 813,031 shares of the company’s stock worth $2,829,000 after purchasing an additional 432,503 shares during the last quarter. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Trading Up 2.3 %

NASDAQ:AUTL opened at $3.08 on Friday. Autolus Therapeutics plc has a 1 year low of $2.94 and a 1 year high of $7.45. The firm’s fifty day simple moving average is $3.91 and its 200 day simple moving average is $3.98. The firm has a market capitalization of $819.56 million, a PE ratio of -2.55 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same quarter last year, the business posted ($0.26) EPS. As a group, analysts anticipate that Autolus Therapeutics plc will post -0.84 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on AUTL shares. Needham & Company LLC restated a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a research note on Monday, November 11th. Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a research note on Friday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $9.45.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.